{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T19:00:20Z","timestamp":1795287620056,"version":"4.10.3"},"reference-count":49,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7,26]]},"abstract":"<jats:p>Adults and children with high-risk CRLF2-rearranged acute lymphoblastic leukemia (ALL) respond poorly to current cytotoxic chemotherapy and suffer unacceptably high rates of relapse, supporting the need to use alternative therapies. CRLF2 encodes the thymic stromal lymphopoietin (TSLP) receptor, which activates cell signaling in normal lymphocytes on binding its ligand, TSLP. We hypothesized that aberrant cell signaling occurs in CRLF2-rearranged ALL and can be targeted by signal transduction inhibitors of this pathway. In a large number of primary CRLF2-rearranged ALL samples, we observed increased basal levels of pJAK2, pSTAT5, and pS6. We thus characterized the biochemical sequelae of CRLF2 and JAK alterations in CRLF2-rearranged ALL primary patient samples via analysis of TSLP-mediated signal transduction. TSLP stimulation of these leukemias further induced robust JAK\/STAT and PI3K\/mTOR pathway signaling. JAK inhibition abrogated phosphorylation of JAK\/STAT and, surprisingly, of PI3K\/mTOR pathway members, suggesting an interconnection between these signaling networks and providing a rationale for testing JAK inhibitors in clinical trials. The PI3K\/mTOR pathway inhibitors rapamycin, PI103, and PP242 also inhibited activated signal transduction and translational machinery proteins of the PI3K\/mTOR pathway, suggesting that signal transduction inhibitors targeting this pathway also may have therapeutic relevance for patients with CRLF2-rearranged ALL and merit further preclinical testing.<\/jats:p>","DOI":"10.1182\/blood-2011-12-389932","type":"journal-article","created":{"date-parts":[[2012,6,9]],"date-time":"2012-06-09T03:59:23Z","timestamp":1339214363000},"page":"833-842","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":212,"title":["Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"120","author":[{"given":"Sarah K.","family":"Tasian","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology-Oncology and"},{"name":"Department of Pediatrics, University of California, San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Y.","family":"Doral","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Borowitz","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology and University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Harvey","sequence":"additional","affiliation":[{"name":"Department of Pathology and University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Gastier-Foster","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Pediatrics, The Ohio State University, Nationwide Children's Hospital, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Willman","sequence":"additional","affiliation":[{"name":"Department of Pathology and University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology\/Bone Marrow Transplantation, Children's Hospital Colorado and The University of Colorado School of Medicine, Aurora, CO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[{"name":"Department of Pathology, St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology and"},{"name":"Department of Pediatrics, University of California, San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111822191642700_B1","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111822191642700_B2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update.","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111822191642700_B3","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111822191642700_B4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia.","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9617","key":"2019111822191642700_B5","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia.","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"2019111822191642700_B6","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2019111822191642700_B7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/pbc.22996","article-title":"Improving outcomes for high-risk ALL: translating new discoveries into clinical care.","volume":"56","author":"Hunger","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"2019111822191642700_B8","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111822191642700_B9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"issue":"23","key":"2019111822191642700_B10","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.","volume":"116","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"9648","key":"2019111822191642700_B11","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"2019111822191642700_B12","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-2141.2008.07552.x","article-title":"Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.","volume":"144","author":"Gaikwad","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111822191642700_B13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2008-08-170928","article-title":"Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.","volume":"113","author":"Kearney","year":"2009","journal-title":"Blood"},{"issue":"23","key":"2019111822191642700_B14","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia.","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111822191642700_B15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1084\/jem.20110580","article-title":"Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias.","volume":"208","author":"Shochat","year":"2011","journal-title":"J Exp Med"},{"issue":"5","key":"2019111822191642700_B16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111822191642700_B17","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2011.128","article-title":"Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles.","volume":"25","author":"Loudin","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"2019111822191642700_B18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/leu.2009.231","article-title":"Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia.","volume":"24","author":"Chapiro","year":"2010","journal-title":"Leukemia"},{"issue":"26","key":"2019111822191642700_B19","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1182\/blood-2009-11-256131","article-title":"Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.","volume":"115","author":"Cario","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2019111822191642700_B20","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","article-title":"Outcome modeling with CRLF2, IKZF1, JAK and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study.","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111822191642700_B21","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/blood-2010-07-297135","article-title":"Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.","volume":"117","author":"Ensor","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111822191642700_B22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2019111822191642700_B23","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2009-05-218560","article-title":"Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111822191642700_B24","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.leu.2402175","article-title":"Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation.","volume":"15","author":"Quentmeier","year":"2001","journal-title":"Leukemia"},{"issue":"4","key":"2019111822191642700_B25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ni.1852","article-title":"Sensing the outside world: TSLP regulates barrier immunity.","volume":"11","author":"Ziegler","year":"2010","journal-title":"Nat Immunol"},{"issue":"2","key":"2019111822191642700_B26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4049\/jimmunol.162.2.677","article-title":"Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism.","volume":"162","author":"Levin","year":"1999","journal-title":"J Immunol"},{"issue":"4","key":"2019111822191642700_B27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/eji.200939419","article-title":"Thymic stromal lymphopoietin induces early human B-cell proliferation and differentiation.","volume":"40","author":"Scheeren","year":"2010","journal-title":"Eur J Immunol"},{"issue":"11","key":"2019111822191642700_B28","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.4049\/jimmunol.163.11.5971","article-title":"Requirement for stat5 in thymic stromal lymphopoietin-mediated signal transduction.","volume":"163","author":"Isaksen","year":"1999","journal-title":"J Immunol"},{"issue":"7","key":"2019111822191642700_B29","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.4049\/jimmunol.168.7.3288","article-title":"Uncoupling of proliferation and Stat5 activation in thymic stromal lymphopoietin-mediated signal transduction.","volume":"168","author":"Isaksen","year":"2002","journal-title":"J Immunol"},{"issue":"6","key":"2019111822191642700_B30","doi-asserted-by":"crossref","first-page":"M112.017764","DOI":"10.1074\/mcp.M112.017764","article-title":"TSLP signaling network revealed by SILAC-based phosphoproteomics.","volume":"11","author":"Zhong","year":"2012","journal-title":"Mol Cell Proteomics"},{"issue":"20","key":"2019111822191642700_B31","doi-asserted-by":"crossref","first-page":"9963","DOI":"10.1158\/0008-5472.CAN-06-4704","article-title":"Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.","volume":"67","author":"Brown","year":"2007","journal-title":"Cancer Res"},{"issue":"1-3","key":"2019111822191642700_B32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12026-008-8038-9","article-title":"Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.","volume":"42","author":"Brown","year":"2008","journal-title":"Immunol Res"},{"issue":"2","key":"2019111822191642700_B33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20111694","article-title":"Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.","volume":"209","author":"Weigert","year":"2012","journal-title":"J Exp Med"},{"issue":"1-2","key":"2019111822191642700_B34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1615\/CritRevOncog.v16.i1-2.30","article-title":"Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.","volume":"16","author":"Tasian","year":"2011","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"2019111822191642700_B35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.1996.14.1.18","article-title":"Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.","volume":"14","author":"Smith","year":"1996","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111822191642700_B36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2008.08.014","article-title":"Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.","volume":"14","author":"Kotecha","year":"2008","journal-title":"Cancer Cell"},{"issue":"1-2","key":"2019111822191642700_B37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(00)00229-5","article-title":"A practical approach to multicolor flow cytometry for immunophenotyping.","volume":"243","author":"Baumgarth","year":"2000","journal-title":"J Immunol Methods"},{"key":"2019111822191642700_B38","doi-asserted-by":"crossref","DOI":"10.1002\/0471142956.cy1017s53","article-title":"Web-based analysis and publication of flow cytometry experiments.","author":"Kotecha","year":"2010","journal-title":"Curr Protoc Cytom"},{"issue":"5","key":"2019111822191642700_B39","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2008-02-137141","article-title":"mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.","volume":"112","author":"Teachey","year":"2008","journal-title":"Blood"},{"issue":"2-3","key":"2019111822191642700_B40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/bc.2010.029","article-title":"Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function.","volume":"391","author":"Wohlmann","year":"2010","journal-title":"Biol Chem"},{"issue":"3","key":"2019111822191642700_B41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update.","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem J"},{"issue":"1","key":"2019111822191642700_B42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/sj.leu.2403560","article-title":"Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support.","volume":"19","author":"Bertrand","year":"2005","journal-title":"Leukemia"},{"issue":"6","key":"2019111822191642700_B43","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1128\/MCB.24.6.2584-2592.2004","article-title":"Absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell development.","volume":"24","author":"Carpino","year":"2004","journal-title":"Mol Cell Biol"},{"key":"2019111822191642700_B44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.immunol.24.021605.090612","article-title":"Development of human lymphoid cells.","volume":"24","author":"Blom","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"2019111822191642700_B45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev.immunol.22.012703.104807","article-title":"Transcriptional control of early B cell development.","volume":"22","author":"Busslinger","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"2019111822191642700_B46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev.immunol.23.021704.115606","article-title":"B cell signaling and tumorigenesis.","volume":"23","author":"Jumaa","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"6030","key":"2019111822191642700_B47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.1198704","article-title":"Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum.","volume":"332","author":"Bendall","year":"2011","journal-title":"Science"},{"issue":"10","key":"2019111822191642700_B48","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nbt.1991","article-title":"Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE.","volume":"29","author":"Qiu","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"31","key":"2019111822191642700_B49","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/4\/833\/1498187\/zh803012000833.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/4\/833\/1498187\/zh803012000833.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T07:19:38Z","timestamp":1687504778000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/4\/833\/105594\/Aberrant-STAT5-and-PI3KmTOR-pathway-signaling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,26]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-12-389932","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,26]]}}}